Capital Research Global Investors Boosts Stock Position in Edwards Lifesciences Corp (NYSE:EW)

Capital Research Global Investors increased its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 3.4% during the 4th quarter, Holdings Channel.com reports. The fund owned 4,672,749 shares of the medical research company’s stock after acquiring an additional 152,377 shares during the period. Capital Research Global Investors’ holdings in Edwards Lifesciences were worth $1,090,106,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Colony Group LLC lifted its position in Edwards Lifesciences by 11.1% in the 3rd quarter. Colony Group LLC now owns 4,178 shares of the medical research company’s stock worth $919,000 after buying an additional 418 shares in the last quarter. Voya Financial Advisors Inc. increased its stake in shares of Edwards Lifesciences by 3.9% in the third quarter. Voya Financial Advisors Inc. now owns 8,722 shares of the medical research company’s stock worth $1,895,000 after acquiring an additional 329 shares during the last quarter. united american securities inc. d b a uas asset management purchased a new stake in shares of Edwards Lifesciences during the third quarter worth $385,000. Highland Capital Management LLC purchased a new stake in shares of Edwards Lifesciences during the third quarter worth $1,419,000. Finally, HWG Holdings LP raised its holdings in shares of Edwards Lifesciences by 40.8% during the third quarter. HWG Holdings LP now owns 13,587 shares of the medical research company’s stock worth $2,988,000 after acquiring an additional 3,937 shares in the last quarter. Institutional investors own 82.68% of the company’s stock.

A number of research analysts have commented on the company. Morgan Stanley boosted their target price on Edwards Lifesciences from $248.00 to $270.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Jefferies Financial Group raised their price target on Edwards Lifesciences from $255.00 to $285.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. Cowen reiterated a “buy” rating and set a $275.00 price target on shares of Edwards Lifesciences in a report on Tuesday, December 17th. BTIG Research assumed coverage on Edwards Lifesciences in a research note on Thursday, February 6th. They issued a “hold” rating for the company. Finally, Piper Sandler increased their price objective on Edwards Lifesciences from $262.00 to $270.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and sixteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $252.95.

Shares of EW stock traded up $6.50 during trading on Thursday, reaching $197.43. The company had a trading volume of 32,969 shares, compared to its average volume of 2,387,790. The firm’s 50 day simple moving average is $209.11 and its two-hundred day simple moving average is $226.01. Edwards Lifesciences Corp has a one year low of $154.52 and a one year high of $247.64. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.31 and a quick ratio of 2.60. The company has a market capitalization of $38.66 billion, a PE ratio of 39.99, a PEG ratio of 1.84 and a beta of 0.80.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, January 30th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.49 by ($0.03). Edwards Lifesciences had a return on equity of 31.73% and a net margin of 24.08%. The company had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.15 billion. During the same period in the previous year, the company earned $1.17 EPS. The firm’s revenue for the quarter was up 20.1% compared to the same quarter last year. Analysts forecast that Edwards Lifesciences Corp will post 6.26 earnings per share for the current year.

In other news, CEO Michael A. Mussallem sold 22,850 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $231.36, for a total transaction of $5,286,576.00. Following the completion of the transaction, the chief executive officer now directly owns 69,976 shares in the company, valued at $16,189,647.36. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Catherine M. Szyman sold 1,116 shares of the stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $162.95, for a total value of $181,852.20. Following the completion of the sale, the vice president now directly owns 15,773 shares of the company’s stock, valued at $2,570,210.35. The disclosure for this sale can be found here. Insiders sold 91,374 shares of company stock valued at $20,894,284 over the last 90 days. 1.63% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Read More: High-Yield Dividend Stocks

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.